薬物スクリーニング市場：製品（消耗品、尿検査機器、分析機器、飲酒検知器、クロマトグラフィー、免疫測定）・サービス、サンプルタイプ（尿、呼気）、エンドユーザー（職場、研究所、刑事司法、病院）別 - 2026年までの世界予測

Drug Screening Market by Product (Consumables, Urine Testing Devices, Analytical, Breathalyzer, Chromatography, Immunoassay) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) - Global Forecast to 2026

世界の薬物スクリーニング市場は、2021年の53億米ドルから、2026年には116億米ドルに達すると予測され、予測期間中のCAGRは16.8%となります。市場の成長は、薬物やアルコールの消費量が増加していること、薬物... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年1月11日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	215	264	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界の薬物スクリーニング市場は、2021年の53億米ドルから、2026年には116億米ドルに達すると予測され、予測期間中のCAGRは16.8%となります。市場の成長は、薬物やアルコールの消費量が増加していること、薬物やアルコールの検査を義務付ける厳格な法律が施行されていること、薬物スクリーニング製品やサービスに対する規制当局の承認が増加していることに大きく起因しています。一方で、イスラム諸国におけるアルコール摂取の禁止や、特定の国における職場での薬物検査の禁止などが、この市場の成長をある程度妨げる可能性があります。

"薬物スクリーニングサービスは、予測期間中に最も高いCAGRで成長すると予想される"
薬物スクリーニング市場は、製品とサービスに分けられます。2020年には、サービス分野が薬物スクリーニング市場の57.4%を占めると予想されています。この分野の成長は、世界的な薬物・アルコール消費量の増加、薬物検査機関への資金提供、サービスの開始や規制当局の承認、薬物検査機関の地理的拡大などの要因に起因しています。

サンプルタイプ別では、尿サンプルが予測期間中に市場を支配すると予想されています。
薬物スクリーニング市場は、サンプルタイプに基づいて、尿、呼気、毛髪、口腔、その他のサンプルに分類されます。尿検体は、採取方法が容易であること、複数の薬物の検出精度が高いこと、費用対効果が高いこと、結果がすぐに得られることなどの利点があり、2020年の薬物スクリーニング市場で最大のシェア61.5%を占めると予想されています。

"予測期間中、北米が市場を支配する"
薬物スクリーニング市場を地理的に見ると、北米、欧州、アジア太平洋地域、その他の地域に分けられます。2020年の薬物スクリーニング市場では、北米が48.2%と最大のシェアを占め、欧州がそれに続きます。しかし、予測期間中、アジア太平洋地域が最も高いCAGR 19.6%を記録すると予想されています。この地域の高成長は、薬物の不法消費の増加、医療インフラの発達、薬物検査に対する厳格な規制ガイドラインの導入の増加によるものです。
本レポートのために行われた主要なインタビューは、以下のように分類されます。
- 企業タイプ別-第1階層：57％、第2階層：30％、第3階層：13％。
- 階層別-Cレベル：30％、Dレベル：45％、その他：25
- 地域別-北米：40％、欧州：19％、アジア太平洋地域：29％、その他の地域：12

薬物スクリーニング市場に参入している著名な企業としては、LabCorp社（米国）、Quest Diagnostics社（米国）、Abbott Laboratories社（米国）、OraSure Technologies社（米国）、Alfa Scientific Designs社（米国）、Thermo Fisher Scientific社（米国）、Drägerwerk社（ドイツ）、LifeLoc社（米国）、MPD Inc.(米国）、Omega Laboratories（米国）、Premier Biotech（米国）、Psychemedics（米国）、Roche（スイス）、Shimadzu（日本）、Siemens Healthineers（ドイツ）。

リサーチカバレッジ
本レポートでは、世界の薬物スクリーニング市場の詳細を明らかにしています。製品やサービス、サンプルタイプ、エンドユーザー、地域など、さまざまなセグメントにおける市場規模と今後の成長性を推定することを目的としています。また、市場の成長に影響を与える要因（推進要因、阻害要因、機会など）を分析しています。ステークホルダーにとっての市場における機会を評価し、市場リーダーにとっての競合状況の詳細を提供しています。また、マイクロマーケットについて、その成長傾向、見通し、および薬物スクリーニング市場全体への貢献度に関して調査しています。このレポートでは、4つの主要地域に関して、市場セグメントの収益を予測しています。

このレポートを購入する理由
本レポートでは、以下の点についての洞察を提供しています。
- 市場への浸透。薬物スクリーニング市場の上位25社が提供する薬物スクリーニングに関する包括的な情報を提供しています。当レポートでは、薬物スクリーニング市場を製品・サービス別、サンプルタイプ別、エンドユーザー別、地域別に分析しています。

- 市場の発展有利な新興市場に関する包括的な情報です。当レポートでは、主要地域における各種薬物スクリーニングの市場を分析しています。

- 市場の多様化新製品やサービス、未開拓の地域、最近の開発状況、薬物スクリーニング市場への投資などに関する網羅的な情報を提供しています。

- 競合評価薬物スクリーニング市場における主要企業の市場ランキングと戦略を詳細に評価します。

ページTOPに戻る

1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
1.3.2 YEARS CONSIDERED FOR THE STUDY 34
1.4 CURRENCY 34
1.5 LIMITATIONS 34
1.6 MARKET STAKEHOLDERS 34
1.7 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 1 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Key data from secondary sources 38
2.1.2 PRIMARY DATA 38
FIGURE 2 PRIMARY SOURCES 39
2.1.2.1 Key industry insights 40
2.1.2.2 Breakdown of primary interviews 40
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION,
AND REGION 40
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER
AND REGION 41
2.2 MARKET SIZE ESTIMATION 41
2.2.1 TOTAL MARKET SIZE: DRUG SCREENING MARKET 41
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 42
FIGURE 6 BOTTOM-UP APPROACH: NO OF TESTING VOLUME BASED ESTIMATION 43
2.2.2 TOP-DOWN APPROACH: CONTRIBUTION-BASED MARKET SIZE ESTIMATION 45
FIGURE 7 DRUG SCREENING MARKET: TOP-DOWN APPROACH 45
2.2.3 GROWTH FORECAST 45
FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE DRUG SCREENING MARKET (2021–2026) 46
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 47
FIGURE 10 DATA TRIANGULATION METHODOLOGY 47
2.4 ASSUMPTIONS FOR THE STUDY 48
2.5 RISK ASSESSMENT 48
TABLE 1 RISK ASSESSMENT: DRUG SCREENING MARKET 48
2.6 LIMITATIONS 48
3 EXECUTIVE SUMMARY 49
FIGURE 11 DRUG SCREENING SERVICES MARKET TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD 49
FIGURE 12 ANALYTICAL INSTRUMENTS SEGMENT TO DOMINATE THE DRUG SCREENING PRODUCTS MARKET, 2021–2026 (USD MILLION) 50
FIGURE 13 DRUG TESTING LABORATORIES ARE EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE END-USER MARKET DURING THE FORECAST PERIOD (USD MILLION) 50
FIGURE 14 GEOGRAPHIC SNAPSHOT OF THE DRUG SCREENING MARKET 51
4 PREMIUM INSIGHTS 52
4.1 DRUG SCREENING MARKET OVERVIEW 52
FIGURE 15 GROWING CONSUMPTION OF ILLICIT DRUGS AND ALCOHOL TO DRIVE MARKET GROWTH 52
4.2 DRUG SCREENING MARKET, BY PRODUCT & SERVICE 52
FIGURE 16 SERVICES SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD (USD MILLION) 52
4.3 DRUG SCREENING MARKET, BY SAMPLE TYPE 53
FIGURE 17 ORAL FLUID SAMPLES SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD (USD MILLION) 53
4.4 DRUG SCREENING MARKET: GEOGRAPHIC SNAPSHOT 53
FIGURE 18 INDIA TO WITNESS THE HIGHEST GROWTH RATE IN THE DRUG SCREENING MARKET DURING THE FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 19 DRUG SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 Growing drug & alcohol consumption 55
5.2.1.2 Enforcement of stringent laws mandating drug & alcohol testing 55
5.2.1.3 Rising regulatory approvals for drug screening products & services 56
TABLE 2 KEY PRODUCT & SERVICE LAUNCHES (2018–2021) 56
TABLE 3 RECENT APPROVALS FOR DRUG & ALCOHOL TESTING PRODUCTS & SERVICES 56
5.2.2 RESTRAINTS 57
5.2.2.1 Ban on alcohol consumption in several Islamic countries 57
5.2.2.2 Prohibition on workplace drug testing in specific countries 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Oral fluid testing 57
5.2.3.2 Fingerprint-based drug testing 57
5.2.3.3 Emerging economies 58
5.2.4 CHALLENGES 58
5.2.4.1 Accuracy and specificity concerns related to breathalyzers 58
5.3 VALUE CHAIN ANALYSIS 59
FIGURE 20 DRUG SCREENING MARKET: VALUE CHAIN ANALYSIS 59
5.4 ECOSYSTEM ANALYSIS 60
FIGURE 21 ECOSYSTEM: DRUG SCREENING MARKET 60
TABLE 4 ROLE OF MARKET PLAYERS IN THE DRUG SCREENING ECOSYSTEM 61
5.5 IMPACT OF COVID 19 ON DRUG SCREENING MARKET 61
5.6 PORTER’S FIVE FORCES ANALYSIS 62
TABLE 5 DRUG SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS 62
5.6.1 DEGREE OF COMPETITION 62
5.6.2 BARGAINING POWER OF SUPPLIERS 62
5.6.3 BARGAINING POWER OF BUYERS 63
5.6.4 THREAT OF SUBSTITUTES 63
5.6.5 THREAT OF NEW ENTRANTS 63
5.7 TECHNOLOGY ANALYSIS 63
5.8 REGULATORY ANALYSIS 64
5.8.1 REGULATORY ASPECTS OF WORKPLACE DRUG TESTING 64
5.8.1.1 US 64
5.8.1.1.1 Substance Abuse and Mental Health Services Administration (SAMSHA) 64
5.8.1.1.1.1 Federal workplace drug testing 64
5.8.1.1.1.2 Federal laws and regulations 64
5.8.1.1.2 Department of Transportation (DOT) 65
TABLE 6 US: DRUG AND ALCOHOL TESTING REGULATIONS 66
5.8.1.2 Europe 66
5.8.1.2.1 Finland 66
5.8.1.2.2 Sweden 66
5.8.1.2.3 France 66
5.8.1.2.4 Italy 67
5.8.1.2.5 United Kingdom 67
5.8.1.2.6 Netherlands 67
5.8.1.2.7 Ireland 67
5.8.1.3 Australia and New Zealand 67
5.9 PATENT ANALYSIS 68
5.10 CASE STUDY ANALYSIS 69
5.10.1 LEADING RETAIL CHAIN SAVES $1 MILLION WITH INSTANT ORAL FLUID EMPLOYEE DRUG SCREEN SOLUTION 69
5.10.2 A BETTER AND INCREASINGLY EFFICIENT DRUG SCREENING SYSTEM 69
5.10.3 PRE-EMPLOYMENT TESTING-LONG TERM CARE INDUSTRY 69
5.10.4 HAIR TESTING VS. URINALYSIS (TRANSPORTATION INDUSTRY) 70
5.10.5 RANDOM TESTING (MANUFACTURING/AUTOMOTIVE) 70
5.10.6 CONTRACTOR TESTING (OIL/GAS) 70
5.10.7 KINGS TRANSPORT-DRUG AND ALCOHOL TESTING 71
6 DRUG SCREENING MARKET, BY PRODUCT & SERVICE 72
6.1 INTRODUCTION 73
TABLE 7 DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 73
6.2 DRUG SCREENING SERVICES 73
6.2.1 ADVANCED DRUG SCREENING TESTS & SERVICES TO DRIVE THE GROWTH OF THIS SEGMENT 73
TABLE 8 DRUG SCREENING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 74
6.3 DRUG SCREENING PRODUCTS 74
TABLE 9 DRUG SCREENING PRODUCT MARKET, BY TYPE, 2019–2026 (USD MILLION) 74
6.3.1 ANALYTICAL INSTRUMENTS 74
TABLE 10 DRUG SCREENING PRODUCT MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2019–2026 (USD MILLION) 75
TABLE 11 DRUG SCREENING PRODUCTS MARKET FOR ANALYTICAL INSTRUMENTS,
BY REGION, 2019–2026 (USD MILLION) 75
6.3.1.1 Breathalyzers 75
6.3.1.1.1 Law enforcement agencies widely use breathalyzers 75
TABLE 12 BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 76
TABLE 13 BREATHALYZERS MARKET, BY REGION, 2019–2026 (USD MILLION) 76
6.3.1.1.2 Fuel-cell breathalyzers 76
TABLE 14 FUEL-CELL BREATHALYZERS MARKET, BY REGION,
2019–2026 (USD MILLION) 77
6.3.1.1.3 Semiconductor breathalyzers 77
TABLE 15 SEMICONDUCTOR BREATHALYZERS MARKET, BY REGION,
2019–2026 (USD MILLION) 77
6.3.1.1.4 Other breathalyzers 77
TABLE 16 OTHER BREATHALYZERS MARKET, BY REGION, 2019–2026 (USD MILLION) 78
6.3.1.2 Immunoassay analyzers 78
6.3.1.2.1 North America is the largest market for immunoassay analyzers 78
TABLE 17 IMMUNOASSAY ANALYZERS MARKET, BY REGION,
2019–2026 (USD MILLION) 79
6.3.1.3 Chromatography instruments 79
6.3.1.3.1 Chromatography techniques show higher accuracy than immunoassays 79
TABLE 18 CHROMATOGRAPHY INSTRUMENTS MARKET, BY REGION,
2019–2026 (USD MILLION) 79
6.3.2 RAPID TESTING DEVICES 80
TABLE 19 DRUG SCREENING PRODUCT MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 80
TABLE 20 DRUG SCREENING PRODUCT MARKET FOR RAPID TESTING DEVICES,
BY REGION, 2019–2026 (USD MILLION) 80
6.3.2.1 Urine testing devices 80
6.3.2.1.1 Urine testing provides results within minutes and is used in a wide range of applications 80
TABLE 21 URINE TESTING DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 81
TABLE 22 URINE TESTING DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 81
6.3.2.1.2 Drug testing cups 81
TABLE 23 DRUG TESTING CUPS MARKET, BY REGION, 2019–2026 (USD MILLION) 81
6.3.2.1.3 Dip cards 82
TABLE 24 DIP CARDS MARKET, BY REGION, 2019–2026 (USD MILLION) 82
6.3.2.1.4 Drug testing cassettes 82
TABLE 25 DRUG TESTING CASSETTES MARKET, BY REGION,
2019–2026 (USD MILLION) 82
6.3.2.2 Oral fluid testing devices 83
6.3.2.2.1 Short detection windows, noninvasive nature, and low chance of sample tampering ensures the demand for oral fluid testing 83
TABLE 26 ORAL FLUID TESTING DEVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 83
6.3.3 CONSUMABLES 83
TABLE 27 DRUG SCREENING CONSUMABLES MARKET, BY TYPE,
2019–2026 (USD MILLION) 83
TABLE 28 DRUG SCREENING CONSUMABLES MARKET, BY REGION,
2019–2026 (USD MILLION) 84
6.3.3.1 Assay kits 84
6.3.3.1.1 Immunoassay kits provide a rapid and inexpensive method to screen samples 84
TABLE 29 ASSAY KITS MARKET, BY REGION, 2019–2026 (USD MILLION) 84
6.3.3.2 Sample collection devices 85
6.3.3.2.1 Sample collection devices see wide usage in drug testing laboratories 85
TABLE 30 SAMPLE COLLECTION DEVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 85
6.3.3.3 Calibrators & controls 85
TABLE 31 CALIBRATORS & CONTROLS MARKET, BY REGION,
2019–2026 (USD MILLION) 86
6.3.3.4 Other consumables 86
TABLE 32 OTHER CONSUMABLES MARKET, BY REGION, 2019–2026 (USD MILLION) 86
7 DRUG SCREENING MARKET, BY SAMPLE TYPE 87
7.1 INTRODUCTION 88
TABLE 33 DRUG SCREENING MARKET, BY SAMPLE TYPE, 2019–2026 (USD MILLION) 88
7.2 URINE SAMPLES 88
7.2.1 EASE OF COLLECTION AND NONINVASIVENESS HAS SUPPORTED THE USE OF URINE SAMPLES 88
TABLE 34 DRUG SCREENING MARKET FOR URINE SAMPLES, BY REGION,
2019–2026 (USD MILLION) 89
7.3 BREATH SAMPLES 89
7.3.1 BREATH ALCOHOL TESTS SEE WIDE USAGE IN WORKPLACE TESTING AND LAW ENFORCEMENT APPLICATIONS 89
TABLE 35 DRUG SCREENING MARKET FOR BREATH SAMPLES, BY REGION,
2019–2026 (USD MILLION) 89
7.4 ORAL FLUID SAMPLES 90
7.4.1 NONINVASIVE SAMPLE COLLECTION AND LOW CHANCE OF ADULTERATION HAVE SUPPORTED THE USAGE OF ORAL FLUID SAMPLES 90
TABLE 36 DRUG SCREENING MARKET FOR ORAL FLUID SAMPLES, BY REGION,
2019–2026 (USD MILLION) 90
7.5 HAIR SAMPLES 91
7.5.1 HAIR SAMPLES CAN PROVIDE INSIGHTS INTO LONG-TERM DRUG USE 91
TABLE 37 DRUG SCREENING MARKET FOR HAIR SAMPLES, BY REGION,
2019–2026 (USD MILLION) 91
7.6 OTHER SAMPLES 92
TABLE 38 DRUG SCREENING MARKET FOR OTHER SAMPLES, BY REGION,
2019–2026 (USD MILLION) 92
8 DRUG SCREENING MARKET, BY END USER 93
8.1 INTRODUCTION 94
TABLE 39 DRUG SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 94
8.2 DRUG TESTING LABORATORIES 94
8.2.1 DRUG TESTING LABORATORIES TO EXHIBIT THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 94
TABLE 40 DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES, BY REGION, 2019–2026 (USD MILLION) 95
8.3 WORKPLACES 95
8.3.1 THE RISING NUMBER OF DRUG ABUSE CASES HAS RESULTED IN AN INCREASE IN WORKPLACE TESTING 95
TABLE 41 DRUG SCREENING MARKET FOR WORKPLACES, BY REGION,
2019–2026 (USD MILLION) 95
TABLE 42 US: DRUG SCREENING MARKET, BY WORKPLACE TYPE,
2019–2026 (USD MILLION) 96
8.4 CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES 96
8.4.1 URINE IS THE MOST COMMONLY USED SAMPLE IN CRIMINAL JUSTICE SYSTEMS 96
TABLE 43 DRUG SCREENING MARKET FOR CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES, BY REGION, 2019–2026 (USD MILLION) 97
8.5 HOSPITALS 97
8.5.1 RISING INCIDENCE OF DRUG ABUSE HAS RESULTED IN AN INCREASE IN EMERGENCY DEPARTMENT VISITS 97
TABLE 44 DRUG SCREENING MARKET FOR HOSPITALS, BY REGION,
2019–2026 (USD MILLION) 97
8.6 DRUG TREATMENT CENTERS 98
8.6.1 AVAILABILITY OF GOVERNMENT SUPPORT IS A KEY GROWTH DRIVER FOR REHABILITATION CENTERS 98
TABLE 45 DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS, BY REGION, 2019–2026 (USD MILLION) 98
8.7 INDIVIDUAL USERS 98
8.7.1 PERSONAL BREATHALYZERS ARE WITNESSING INCREASING ADOPTION DUE TO STRINGENT DUI REGULATIONS 98
TABLE 46 DRUG SCREENING MARKET FOR INDIVIDUAL USERS, BY REGION,
2019–2026 (USD MILLION) 99
8.8 PAIN MANAGEMENT CENTERS 99
8.8.1 RISING SUBSTANCE ABUSE HAS SUPPORTED DRUG TESTING IN PAIN MANAGEMENT APPLICATIONS 99
TABLE 47 DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS, BY REGION, 2019–2026 (USD MILLION) 100
8.9 SCHOOLS AND COLLEGES 100
8.9.1 DRUG ABUSE TESTING PROGRAMS HAVE BEEN INTRODUCED IN SCHOOLS TO CURB DRUG ABUSE 100
TABLE 48 DRUG SCREENING MARKET FOR SCHOOLS AND COLLEGES, BY REGION, 2019–2026 (USD MILLION) 100
9 DRUG SCREENING MARKET, BY REGION 101
9.1 INTRODUCTION 102
TABLE 49 DRUG SCREENING MARKET, BY REGION, 2019–2026 (USD MILLION) 102
9.2 NORTH AMERICA 103
FIGURE 22 NORTH AMERICA: DRUG SCREENING MARKET SNAPSHOT 103
TABLE 50 NORTH AMERICA: DRUG SCREENING MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 104
TABLE 51 NORTH AMERICA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 104
TABLE 52 NORTH AMERICA: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 104
TABLE 53 NORTH AMERICA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 105
TABLE 54 NORTH AMERICA: BREATHALYZERS MARKET, BY TYPE,
2019–2026 (USD MILLION) 105
TABLE 55 NORTH AMERICA: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 105
TABLE 56 NORTH AMERICA: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 106
TABLE 57 NORTH AMERICA: CONSUMABLES MARKET, BY TYPE,
2019–2026 (USD MILLION) 106
TABLE 58 NORTH AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 106
TABLE 59 NORTH AMERICA: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 107
9.2.1 US 107
9.2.1.1 The US holds the largest share of the drug screening market
in North America 107
TABLE 60 US: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 108
TABLE 61 US: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 108
TABLE 62 US: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 109
TABLE 63 US: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 64 US: RAPID TESTING DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 65 US: URINE TESTING DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 66 US: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 110
TABLE 67 US: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 110
TABLE 68 US: DRUG SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 110
9.2.2 CANADA 111
9.2.2.1 The high rate of DUI-related accidental deaths is expected to drive the use of breathalyzers in this market 111
TABLE 69 CANADA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 112
TABLE 70 CANADA: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 112
TABLE 71 CANADA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 112
TABLE 72 CANADA: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 73 CANADA: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 113
TABLE 74 CANADA: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 113
TABLE 75 CANADA: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 114
TABLE 76 CANADA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 114
TABLE 77 CANADA: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 114
9.3 EUROPE 115
TABLE 78 EUROPE: DRUG SCREENING MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 115
TABLE 79 EUROPE: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 115
TABLE 80 EUROPE: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 116
TABLE 81 EUROPE: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 116
TABLE 82 EUROPE: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 116
TABLE 83 EUROPE: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 116
TABLE 84 EUROPE: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 117
TABLE 85 EUROPE: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 86 EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 117
TABLE 87 EUROPE: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 118
9.3.1 GERMANY 118
9.3.1.1 The rising number of drug-related deaths in Germany drives
the demand for drug screening products & services 118
TABLE 88 GERMANY: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 118
TABLE 89 GERMANY: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 119
TABLE 90 GERMANY: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 119
TABLE 91 GERMANY: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 119
TABLE 92 GERMANY: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 119
TABLE 93 GERMANY: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 94 GERMANY: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 120
TABLE 95 GERMANY: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 120
TABLE 96 GERMANY: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 121
9.3.2 FRANCE 121
9.3.2.1 Cannabis and cocaine are the most widely used illicit substances in France 121
TABLE 97 FRANCE: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 121
TABLE 98 FRANCE: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 122
TABLE 99 FRANCE: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 122
TABLE 100 FRANCE: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 122
TABLE 101 FRANCE: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 122
TABLE 102 FRANCE: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 123
TABLE 103 FRANCE: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 104 FRANCE: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 123
TABLE 105 FRANCE: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 124
9.3.3 UK 124
9.3.3.1 Favorable government support is a key growth driver for the UK market 124
TABLE 106 UK: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 125
TABLE 107 UK: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 125
TABLE 108 UK: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 125
TABLE 109 UK: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 110 UK: RAPID TESTING DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 111 UK: URINE TESTING DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 112 UK: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 113 UK: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 127
TABLE 114 UK: DRUG SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 127
9.3.4 ITALY 127
9.3.4.1 Cannabis is the most widely used illicit drug among adolescents
in Italy 127
TABLE 115 ITALY: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 128
TABLE 116 ITALY: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 128
TABLE 117 ITALY: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 128
TABLE 118 ITALY: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 129
TABLE 119 ITALY: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 129
TABLE 120 ITALY: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 129
9.3.5 SPAIN 130
9.3.5.1 Cannabis and cocaine are the most widely used drugs in Spain among adolescents and adults 130
TABLE 121 SPAIN: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 130
TABLE 122 SPAIN: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 123 SPAIN: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 124 SPAIN: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 131
TABLE 125 SPAIN: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 132
TABLE 126 SPAIN: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 132
9.3.6 ROE 132
TABLE 127 ROE: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 133
TABLE 128 ROE: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 133
TABLE 129 ROE: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 134
TABLE 130 ROE: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 134
TABLE 131 ROE: RAPID TESTING DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 134
TABLE 132 ROE: URINE TESTING DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 134
TABLE 133 ROE: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 134 ROE: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 135
TABLE 135 ROE: DRUG SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 135
9.4 ASIA PACIFIC (APAC) 136
FIGURE 23 APAC: DRUG SCREENING MARKET SNAPSHOT 136
TABLE 136 APAC: DRUG SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 137
TABLE 137 APAC: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 137
TABLE 138 APAC: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 137
TABLE 139 APAC: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 140 APAC: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 138
TABLE 141 APAC: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 142 APAC: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 138
TABLE 143 APAC: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 139
TABLE 144 APAC: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 139
TABLE 145 APAC: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 139
9.4.1 CHINA 140
9.4.1.1 China accounted for the largest share of the drug screening market in the APAC region in 2020 140
TABLE 146 CHINA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 140
TABLE 147 CHINA: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 140
TABLE 148 CHINA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 149 CHINA: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 150 CHINA: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 151 CHINA: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 152 CHINA: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 142
TABLE 153 CHINA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 142
TABLE 154 CHINA: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 142
9.4.2 JAPAN 143
9.4.2.1 Stringent laws for drug abuse and the growing awareness of drug addiction are key growth drivers in Japan 143
TABLE 155 JAPAN: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 143
TABLE 156 JAPAN: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 144
TABLE 157 JAPAN: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 144
TABLE 158 JAPAN: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 159 JAPAN: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 144
TABLE 160 JAPAN: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 145
TABLE 161 JAPAN: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 162 JAPAN: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 145
TABLE 163 JAPAN: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 146
9.4.3 INDIA 146
9.4.3.1 The increasing burden of DUI-road cases in the country to drive
the growth of the drug screening market 146
TABLE 164 INDIA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 147
TABLE 165 INDIA: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 147
TABLE 166 INDIA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 147
TABLE 167 INDIA: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 168 INDIA: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 148
TABLE 169 INDIA: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 148
TABLE 170 INDIA: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 171 INDIA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 149
TABLE 172 INDIA: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 149
9.4.4 REST OF ASIA PACIFIC (ROAPAC) 149
TABLE 173 ROAPAC: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 150
TABLE 174 ROAPAC: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 150
TABLE 175 ROAPAC: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 176 ROAPAC: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 177 ROAPAC: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 178 ROAPAC: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 179 ROAPAC: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 152
TABLE 180 ROAPAC: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 152
TABLE 181 ROAPAC: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 152
9.5 REST OF THE WORLD (ROW) 153
TABLE 182 ROW: DRUG SCREENING MARKET, BY REGION, 2019–2026 (USD MILLION) 153
TABLE 183 ROW: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 153
TABLE 184 ROW: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 153
TABLE 185 ROW: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 154
TABLE 186 ROW: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 154
TABLE 187 ROW: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 154
TABLE 188 ROW: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 154
TABLE 189 ROW: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 155
TABLE 190 ROW: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 155
TABLE 191 ROW: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 155
9.5.1 LATAM 156
9.5.1.1 Increasing incidence of drug overdose and favorable government support are key growth drivers in this region 156
TABLE 192 LATAM: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 156
TABLE 193 LATAM: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 156
TABLE 194 LATAM: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 157
TABLE 195 LATAM: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 196 LATAM: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 157
TABLE 197 LATAM: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 157
TABLE 198 LATAM: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 199 LATAM: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 158
TABLE 200 LATAM: DRUG SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 158
9.5.2 MIDDLE EAST & AFRICA 159
9.5.2.1 Rising drug abuse and growing emphasis on drug abuse testing supports the market growth in the MEA region 159
TABLE 201 MEA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 159
TABLE 202 MEA: DRUG SCREENING PRODUCT MARKET, BY TYPE,
2019–2026 (USD MILLION) 159
TABLE 203 MEA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 160
TABLE 204 MEA: BREATHALYZERS MARKET, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 205 MEA: RAPID TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 160
TABLE 206 MEA: URINE TESTING DEVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 160
TABLE 207 MEA: CONSUMABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 161
TABLE 208 MEA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2019–2026 (USD MILLION) 161
TABLE 209 MEA: DRUG SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 161
10 COMPETITIVE LANDSCAPE 162
10.1 OVERVIEW 162
FIGURE 24 KEY DEVELOPMENTS OF PROMINENT PLAYERS OPERATING IN THE DRUG SCREENING MARKET (2018-2021) 162
10.2 MARKET RANKING 163
FIGURE 25 DRUG SCREENING SERVICES MARKET RANKING, BY KEY PLAYER, 2020 163
FIGURE 26 RAPID TESTING DEVICES MARKET RANKING, BY KEY PLAYER, 2020 163
10.3 COMPANY EVALUATION QUADRANT 165
10.3.1 STARS 165
10.3.2 EMERGING LEADERS 165
10.3.3 PERVASIVE PLAYERS 165
10.3.4 PARTICIPANTS 165
FIGURE 27 DRUG SCREENING MARKET: COMPANY EVALUATION QUADRANT,
2020 (OVERALL MARKET) 166
10.4 COMPANY EVALUATION QUADRANT FOR EMERGING PLAYERS 167
10.4.1 PROGRESSIVE COMPANIES 167
10.4.2 STARTING BLOCKS 167
10.4.3 RESPONSIVE COMPANIES 167
10.4.4 DYNAMIC COMPANIES 167
FIGURE 28 DRUG SCREENING MARKET: COMPANY EVALUATION QUADRANT,
2020 (EMERGING PLAYERS) 168
10.5 COMPETITIVE BENCHMARKING 169
10.5.1 OVERALL COMPANY FOOTPRINT 169
TABLE 210 OVERALL COMPANY FOOTPRINT 169
10.5.2 COMPANY PRODUCT AND SERVICE FOOTPRINT 169
TABLE 211 COMPANY PRODUCT AND SERVICE FOOTPRINT 169
10.5.3 COMPANY PRODUCTS FOOTPRINT 170
TABLE 212 COMPANY PRODUCT FOOTPRINT 170
10.5.4 COMPANY REGION FOOTPRINT 170
TABLE 213 COMPANY REGION FOOTPRINT 170
10.6 COMPETITIVE SCENARIO 171
TABLE 214 PRODUCT LAUNCHES & APPROVALS (JANUARY 2018 ─JUNE2021) 171
TABLE 215 DEALS (JANUARY 2018─AUGUST 2021) 172
TABLE 216 OTHER DEVELOPMENTS (JANUARY 2018– JUNE 2021) 173
11 COMPANY PROFILES 174
11.1 KEY PLAYERS 174
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 LABCORP 174
TABLE 217 LABCORP: BUSINESS OVERVIEW 174
FIGURE 29 LABCORP: COMPANY SNAPSHOT (2020) 175
11.1.2 QUEST DIAGNOSTICS 177
TABLE 218 QUEST DIAGNOSTICS: BUSINESS OVERVIEW 177
FIGURE 30 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2020) 177
11.1.3 ABBOTT LABORATORIES 180
TABLE 219 ABBOTT LABORATORIES: BUSINESS OVERVIEW 180
FIGURE 31 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 181
11.1.4 ORASURE TECHNOLOGIES 184
TABLE 220 ORASURE TECHNOLOGIES: BUSINESS OVERVIEW 184
FIGURE 32 ORASURE TECHNOLOGIES: COMPANY SNAPSHOTS (2020) 185
11.1.5 ALFA SCIENTIFIC DESIGNS 187
TABLE 221 ALFA SCIENTIFIC DESIGNS: BUSINESS OVERVIEW 187
11.1.6 THERMO FISHER SCIENTIFIC 189
TABLE 222 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 189
FIGURE 33 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOTS (2020) 190
11.1.7 DRÄGERWERK 193
TABLE 223 DRÄGERWERK: BUSINESS OVERVIEW 193
FIGURE 34 DRÄGERWERK: COMPANY SNAPSHOT (2020) 194
11.1.8 LIFELOC TECHNOLOGIES 196
TABLE 224 LIFELOC TECHNOLOGIES: BUSINESS OVERVIEW 196
FIGURE 35 LIFELOC: COMPANY SNAPSHOT (2020) 196
11.1.9 MPD INC. 199
TABLE 225 MPD INC: BUSINESS OVERVIEW 199
11.1.10 OMEGA LABORATORIES 201
TABLE 226 OMEGA LABORATORIES: BUSINESS OVERVIEW 201
11.1.11 PREMIER BIOTECH 202
TABLE 227 PREMIER BIOTECH: BUSINESS OVERVIEW 202
11.1.12 PSYCHEMEDICS 203
TABLE 228 PSYCHEMEDICS: BUSINESS OVERVIEW 203
FIGURE 36 PSYCHEMEDICS: COMPANY SNAPSHOT (2020) 203
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 205
11.2.1 ROCHE 205
11.2.2 SHIMADZU 206
11.2.3 SIEMENS HEALTHINEERS 207
11.2.4 AMERICAN BIO MEDICA CORPORATION 208
11.2.5 ACM GLOBAL LABORATORIES 209
11.2.6 CAREHEALTH AMERICA CORP 210
11.2.7 CLINICAL REFERENCE LABORATORY 211
11.2.8 INTOXIMETERS 212
11.2.9 SCITECK, INC. 213
11.2.10 ACCUSOURCE 214
11.2.11 CORDANT HEALTH SOLUTIONS 214
11.2.12 SYNENS 215
11.2.13 MILLENNIUM HEALTH 215
12 APPENDIX 216
12.1 DISCUSSION GUIDE 216
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 220
12.3 AVAILABLE CUSTOMIZATIONS 222
12.4 RELATED REPORTS 222
12.5 AUTHOR DETAILS 223

ページTOPに戻る

Table of Contents

Summary

The global drug screening market is projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a CAGR of 16.8% during the forecast period. Market growth can be largely attributed to the growing drug & alcohol consumption and the enforcement of stringent laws mandating drug & alcohol testing, rising regulatory approvals for drug screening products & services. On the other hand, bans on alcohol consumption in Islamic countries and prohibitions on workplace drug testing in specific countries may hinder the growth of this market to a certain extent.

“Drug screening services are expected to grow at the highest CAGR during the forecast period”
Drug screening market is segmented into products and services. In 2020,the services segment is expected to hold the largest share 57.4% of the drug screening market, growth in this segment is attributed to factors such growing drug & alcohol consumption worldwide, funding initiatives for drug testing laboratories, service launches and regulatory approvals, and geographic expansion of drug testing laboratories.

By sample type, urine samples are expected to dominate the market during the forecast period”
The drug screening market is segmented into urine, breath, hair, oral, and other samples on the basis of sample type. The urine sample segment is expected to hold the largest share 61.5% of the drug screening market in 2020 due to the benefits it offers such as easy collection method, high accuracy in the detection of multiple drugs, cost-effectiveness, and instant results.

“North America will dominate the market during the forecast period.”
Geographically, the drug screening market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2020, North America accounted for the largest share of 48.2% of the drug screening marke tfollowed by Europe. However, Asia Pacific is expected to register the highest CAGR 19.6% during the forecast period. The high growth of this regional segment is attributed due to the growing illicit consumption of drugs, the developing healthcare infrastructure and rising adoption of stringent regulatory guidelines for drug testing.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type -Tier 1: 57%, Tier 2: 30%,and Tier 3: 13%
• By Designation - C-level:30%, D-level:45%, and Others:25%
• By Region - North America:40%, Europe:19%, Asia Pacific:29%, and Rest of the World: 12%

Some of the prominent players operating in the drug screening market are LabCorp (US), Quest Diagnostics (US), Abbott Laboratories (US), OraSure Technologies (US), Alfa Scientific Designs (US), Thermo Fisher Scientific (US), Drägerwerk (Germany), LifeLoc (US), MPD Inc. (US), Omega Laboratories (US), Premier Biotech (US), Psychemedics (US), Roche (Switzerland), Shimadzu (Japan), and Siemens Healthineers (Germany).

Research Coverage:
This report provides a detailed picture of the global drug screening market. It aims at estimating the size and future growth potential of the market across different segments, such as product and service, sample type, end user,and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total drug screening market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on drug screening offered by the top 25 players in the drug screening market. The report analyses the drug screening market by product and service, sample type, end user, and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various drug screening across key geographic regions.

• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the drug screening market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the drug screening market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（consumables）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（consumables）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?